A mathematical model of parathyroid gland biology

Gudrun Schappacher-Tilp¹, Alhaji Cherif²,³, Doris H. Fuertinger⁴, David Bushinsky⁵ & Peter Kotanko²,⁶

1 Department of Mathematics and Scientific Computing, University of Graz, Graz, Austria
2 Renal Research Institute, New York City, New York
3 School of Mathematical and Statistical Sciences, Arizona State University, Tempe, Arizona
4 Global Research and Development, Fresenius Medical Care Germany, Bad Homburg, Germany
5 Division of Nephrology, Department of Medicine, University of Rochester School of Medicine, Rochester, New York
6 Icahn School of Medicine at Mount Sinai, New York City, New York

Keywords
Mathematical model, Parathyroid hormone, Calcium-sensing receptor, Parathyroid gland.

Abstract
Altered parathyroid gland biology in patients with chronic kidney disease (CKD) is a major contributor to chronic kidney disease-mineral bone disorder (CKD-MBD). This disorder is associated with an increased risk of bone disorders, vascular calcification, and cardiovascular events. Parathyroid hormone (PTH) secretion is primarily regulated by the ionized calcium concentration as well as the phosphate concentration in the extracellular fluid and vitamin D. The metabolic disturbances in patients with CKD lead to alterations in the parathyroid gland biology. A hallmark of CKD is secondary hyperparathyroidism, characterized by an increased production and release of PTH, reduced expression of calcium-sensing and vitamin D receptors on the surface of parathyroid cells, and hyperplasia and hypertrophy of these cells. These alterations happen on different timescales and influence each other, thereby triggering a cascade of negative and positive feedback loops in a highly complex manner. Due to this complexity, mathematical models are a useful tool to break down the patterns of the multidimensional cascade of processes enabling the detailed study of subsystems. Here, we introduce a comprehensive mathematical model that includes the major adaptive mechanisms governing the production, secretion, and degradation of PTH in patients with CKD on hemodialysis. Combined with models for medications targeting the parathyroid gland, it provides a ready-to-use tool to explore treatment strategies. While the model is of particular interest for use in hemodialysis patients with secondary hyperparathyroidism, it has the potential to be applicable to other clinical scenarios such as primary hyperparathyroidism or hypo- and hypercalcemia.

Introduction
The concentration of extracellular ionized calcium is maintained within a narrow physiologic range by an exquisite system of negative and positive feedback regulators involving the major organs that transport calcium and phosphate, that is, the intestine, the kidneys, bone, and the endocrine organs, most prominently the parathyroid gland (PTG). To avoid clinical symptoms, the arterial blood extracellular ionized calcium concentration (Ca²⁺) must be maintained within about ±1–2% (Brown 2007).

A key endocrine regulator for Ca²⁺ is parathyroid hormone (PTH) (Pocotte et al. 1991; Nemeth 2002; Silver and Naveh-Many 2009), which increases serum calcium levels by enhancing renal tubular calcium reabsorption, stimulating net bone resorption, and increasing the production of activated vitamin D (1,25(OH)₂D₃) which increases net intestinal calcium absorption. PTH is produced, stored, and eventually released by the PTG. The
PTG consists of two cell populations: active secretory cells and quiescent cells, which are able to proliferate or undergo apoptosis. Secretory active cells produce, store, and release PTH. PTG activity itself is mainly regulated by extracellular Ca\(^{2+}\) which activates the calcium-sensing receptors (CaSR) on the surface of PTG cells (Pocotte et al. 1991; Schmitt et al. 1996).

The CaSR is integrally involved in PTG function and biology and, therefore, the key to understanding pathologies such as secondary hyperparathyroidism. The activation of the CaSR by the binding of Ca\(^{2+}\) initiates several signaling pathways which downregulate PTH release, production, and PTG cellular proliferation rates (Chen and Goodman 2004; Chakravarti et al. 2012; Conigrave and Ward 2013). Moreover, the CaSR regulates PTH mRNA stability (Moallem et al. 1998), thereby mediating its rate of degradation. Besides controlling PTH secretion, synthesis, degradation, and PTG proliferation, the CaSR upregulates vitamin D receptor (VDR) expression (Canalejo et al. 2000).

The PTG adapts swiftly to conditions requiring enhanced PTH secretion, such as hypocalcemia. The different adaptive responses manifest on significantly different timescales, reaction times ranging from minutes to hours, days, and weeks. For instance, in the case of an acute hypocalcemia, the PTG quickly responds by releasing stored PTH within seconds to minutes (Felsenfeld et al. 2007). If hypocalcemia persists, intracellular PTH degradation rate declines within 20 min, thereby increasing the amount of intact PTH that can be released (Schwarz et al. 1993). If normocalcemia is still not attained, the PTH production rate increases within an hour (Habener 1981). Subsequently, the PTG will augment its cellular proliferation rate within 2 days (Tokumoto et al. 2005). In chronic hypocalcemia, the enhanced proliferation rate will lead to hyperplasia whereby the PTG mass increases 10–100 fold or more (Fukagawa et al. 2006) (Fig. 1).

In patients with chronic kidney disease (CKD), the loss of the regulatory kidney function triggers a cascade of processes eventually leading to secondary hyperparathyroidism, an abnormality characterized by increased PTH synthesis and secretion, and PTG cell proliferation. One hallmark of CKD is the impaired renal synthesis of the principal bioactive form of vitamin D, 1,25-dihydroxyvitamin D\(_3\) (1,25D) and the significantly impaired renal clearance of phosphate (Levin et al. 2007). Both 1,25D and phosphate significantly influence CaSR regulation and thereby PTH synthesis and release and PTG proliferation. There is a positive feedback loop between the CaSR and the vitamin D receptor (VDR) expression (Chakravarti et al. 2012) and suppression of CaSR expression at high phosphate levels (Brown et al. 1999). The pathological effects exerted by high phosphate levels are significant. Studies in uremic rats have shown that a high phosphate diet enhances PTG proliferation within a few days (Navehmany et al. 1995; Denda et al. 1996; Slatopolsky et al. 1999). Low calcium intake has a similar effect, but the required time for PTG proliferation is significantly longer. Importantly, the positive feedback loop of CaSR and VDR is effectively diminished in the presence of high phosphate levels (Canalejo et al. 2000).

In CKD, PTH stimulates bone resorption over bone formation, resulting in a net release of Ca\(^{2+}\) and phosphate from the bone into the systemic circulation (Graciloli et al. 2017). As a consequence, PTH and phosphate levels increase even further, and expression of CaSR and VDR is depressed, thus lowering the sensitivity of the PTG to Ca\(^{2+}\) and 1,25D (Borrego et al. 1997; Gogusev et al. 1997). The altered biology eventually results in PTG hyperplasia and secondary hyperparathyroidism (Tokumoto et al. 2005; Goodman and Quarles 2008). Due to

![Figure 1](image_url)
the complexity of the adaptation of PTG biology in patients with CKD on hemodialysis, a mathematical model of the PTG provides a useful tool to study secondary hyperparathyroidism and optimize treatment strategies. In tandem with mathematical models of bone turnover, intestinal calcium and phosphate absorption (Kroll 2000; Lemaire et al. 2004; Peterson and Riggs 2010), the PTG model provides a key element of an in silico model of secondary hyperparathyroidism in CKD and hemodialysis patients, enabling predictions about the development of chronic kidney disease-mineral and bone disorder (CKD-MBD) (Moe et al. 2006; Palmer et al. 2011).

The aim of this study was to develop a mathematical model comprising the main aspects of PTG biology. There are various published models of PTH (Momsen and Schwarz 1997; Raposo et al. 2002; Shrestha et al. 2010; Granjon et al. 2017), some including the adaptation mechanism of the PTG in patients with CKD (Riggs et al. 2012). However, we are not aware of a PTG model that separately captures the structure of the key adaptation mechanisms of the complex network regulating PTH in patients with CKD. We propose a model based on CaSR expression and activity regulated by Ca\(^{2+}\), phosphate, and 1,25D. Our model includes the various mechanisms ensuring enhanced PTH levels acting on different time-scales, thereby allowing predictions for both rapid responses, for example, in the case of induced acute hypocalcemia and long-term adaptations reflecting the transition of the normal PTG into a hyperplastic gland with reduced sensitivity to Ca\(^{2+}\) and 1,25D. We validated the model predictions with published data.

### Mathematical Model

#### Key features

The core of our model is the CaSR. We make use of physiological principles governing the signaling cascade triggered by the CaSR: (1) If all key parameters (i.e., Ca\(^{2+}\), 1,25D, and phosphate) are within their optimal physiologic range, the CaSR signaling will ensure that PTH release rate, production rate, and proliferation rate are downregulated to their basal values and intracellular degradation rate is constant. (2) If one or more key parameters are not in their optimal range for a critical amount of time, CaSR signaling is altered resulting in PTG adaptations regarding PTH release rate, intracellular PTH degradation rate, PTH production rate, and cellular proliferation. The critical amount of time is significantly different for the different CaSR signaling pathways and is seconds for the release rate, minutes for the degradation rate, hours for the production rate, and days for the proliferation rate. (3) Due to the feedback loops acting on the CaSR, the alteration in signaling also changes CaSR expression over time. Less CaSR expression leads to a lower sensitivity of the PTG to blood ionized calcium concentration. (4) We use stimulus functions describing the deviation from the optimal range. Negative stimulus corresponds to values below the optimal range; positive stimulus corresponds to values above the optimal range. (5) Stimulus functions are the same for all adaptation mechanisms. Stimulus functions are chosen such that small deviations from the optimal value will not trigger a response unless these deviations last for an extended period of time. (6) All effects but hyperplasia are reversible. If a condition like acute hypocalcemia is resolved, PTH synthesis rate, intracellular degradation rate, and cellular proliferation rate will return to baseline (Brown 2007; Vervloet et al. 2017). However, since apoptosis rate is assumed to be constant (Navehmany et al. 1995; Takahashi et al. 2002), the PTG size will not decrease.

#### Input parameters

Ionized calcium concentration (Ca\(^{2+}\)), phosphate (P), and 1,25D are the important input parameters. All Ca\(^{2+}\), 1,25D, and P profiles used in PTH predictions are simulated profiles within physiological meaningful ranges. A high-level sketch of the model is provided in Figure 2.

#### Ca\(^{2+}\)

The ionized calcium concentration (provided as an input parameter in this manuscript) regulates the PTG response via the CaSR. We couple the actual ionized calcium concentration and the PTG via the CaSR by equations (1)–(8).

#### CaSR expression

CaSR and VDR expressions are determined in order to assess the overall sensitivity of the receptors to the concentration of the arterial blood ionized calcium and 1,25D concentrations. We model a dimensionless CaSR and VDR expression. The optimal value is normalized to 1 for both variables. Values lower than 1 correspond to a loss of CaSR or VDR expression. Receptor expression is regulated by a positive feedback loop between the CaSR and the VDR (Fig. 3) and is suppressed by phosphate. We therefore assume that the dimensionless CaSR expression, CaSR, and VDR expression, VDR, are governed by the following system of differential equations:

\[
\frac{d\text{CaSR}}{dt} = p_{\text{Ca}} \cdot (v + (VDR - 1) - \pi) \cdot \text{CaSR} + n_{\text{Ca}} \cdot (1 - \text{CaSR}),
\]  

(1)
\[ \frac{d\delta^{in}}{dr} = (\text{stim}_D(D - D_{\text{opt}})) \\
\cdot (1 - \text{sign}(\text{stim}_D(D - D_{\text{opt}}))\delta^{in} - \delta^{in}) \cdot \tau_D \]
\[ \frac{d\pi^{in}}{dr} = (\text{stim}_P(P - P_{\text{opt}})) \\
\cdot (1 - \text{sign}(\text{stim}_P(P - P_{\text{opt}}))\pi^{in} - \pi^{in}) \cdot \tau_P \]

where \( C_{opt} \), \( D_{opt} \), and \( P_{opt} \) are the optimal blood values of \( \text{Ca}^{2+} \), 1,25D, and phosphate. \( CS \) and \( DS \) are defined in equations (6) and (8) and couple the actual blood values of \( \text{Ca}^{2+} \) and 1,25D with the receptor density. \( P \) is the serum phosphate concentration. The intensity of the stimulus and feedback is governed by \( p_{Ca} \) and \( p_{D} \), the relationship between \( p_{Ca} \) and \( n_{Ca} \) as well as \( p_{D} \) and \( n_{D} \) determines the equilibrium of the system. \( \chi^{in} \) and \( \pi^{in} \) are factors determining the effect of the stimulus of \( \text{Ca}^{2+} \), 1,25D, and phosphate on the CaSR and VDR respectively. The time constants \( \tau_D \) and \( \tau_P \) determine the convergence rate to the steady state after a stepwise change in ionized calcium, 1,25D, or phosphate. They are associated with the critical time after which the system starts to react to nonoptimal concentrations of ionized calcium, 1,25D, or phosphate. We use a stimulus function which introduces autoregulation regarding long-term effects. The stimulus functions can be written as

\[ \text{stim}_w(x) = \frac{1}{1 + \exp\left(-K_w(x - W_1)\right)} \\
+ \frac{1}{1 + \exp\left(-K_w(x + W_1)\right)} - 1, \text{and } W \in (C, D, P) \]

where \( K \) and \( W_1 \) are constants. Under optimal conditions, the stimulus functions are zero for ionized calcium, 1,25D, and phosphate. Therefore, \( \chi^{in} \), \( \delta^{in} \), and \( \pi^{in} \) are zero and the CaSR and VDR expressions are not altered. If the deviation from the optimal range is shorter than the critical time associated with the time constants, for example, a brief induced hypocalcemia, the stimulus on \( \chi^{in} \) is too small to change \( \chi^{in} \) significantly. Therefore, CaSR expression will not be altered. However, in the case of a mild but chronic hypocalcemia, CaSR expression will slowly decline after a time lag due to the small but constant stimulus of \( \chi^{in} \). The terraced form of the stimulus function with the small plateau around the optimal values ensures that an insignificant deviation from the optimal values does not trigger the full response of the system such as the increase of cellular proliferation rate. Therefore, the whole system is stabilized but still able to react properly if the deviation is increasing or persistent over a
long period of time. The stimulus function coupled with the delayed response is a simplification of the three-state dimer receptor model, for example (Brea et al. 2009). The formulation of stimulus functions and delayed response replaces well-established but numerically highly unstable delay equations.

**Effect of CaSR and VDR density**

A lower density of CaSR leads to less downstream signaling. Therefore, the same actual Ca$^{2+}$ concentration can lead to different PTG responses in a normal, healthy PTG compared to a gland with reduced CaSR expression (Goodman et al. 1998; Schmitt and Schaefer 1999). The gland with reduced CaSR expression appears less sensitive to Ca$^{2+}$. Therefore, it is not the present ionized calcium level that determines the response of the system but rather the calcium level associated with the CaSR density which is referred to as sensed calcium concentration CS. The same holds for the 1,25D concentration. A gland with reduced VDR expression appears less sensitive to 1,25D and it is not the actual 1,25D concentration but the 1,25D value associated with the VDR sensitivity (DS) which determines the response of the system.

\[
\frac{dCS}{dt} = \text{sens}(\text{CaSR} + \text{VDR})C - CS, \tag{6}
\]

\[
\frac{dDS}{dt} = \text{sens}(\text{CaSR} + \text{VDR})D - DS, \tag{7}
\]

\[
\text{sens}(x) = A_S + (1 - A_S) \cdot (x/2), \tag{8}
\]

where $C$ is the blood ionized calcium concentration and $D$ is the 1,25D plasma concentration. At optimal conditions, the dimensionless CaSR and VDR expressions equal 1, and $CS$ and $DS$ equilibrate to $C$ and $D$. Hence, the sensed calcium concentration equals the actual blood Ca$^{2+}$ concentration. If the dimensionless CaSR expression starts to decline, the sensed calcium concentration $CS$ declines as well but with a slight delay. The maximal rate of decline is $A_S$. This effect is reversible. If the CaSR expression increases again, for example, by long-term effects of a low phosphate diet, 1,25D supplements, or calcimimetics, the sensed calcium concentration $CS$ will approach $C$ again.

**CaSR signaling**

CaSR signaling is directly governed by the sensed ionized calcium concentration $CS$ and phosphate (Silver and Naveh-Many 2009). Furthermore, the activity is indirectly governed by VDR due to the feedback loop between the VDR and CaSR:

\[
\frac{d\delta_0}{dt} = p_o \cdot (\delta_0 - \pi_s) \cdot \delta_0 + n_o \cdot (1 - \delta_0), \tag{9}
\]

\[
\frac{d\pi_s}{dt} = (\text{stim}_{\text{Ca}}(CS - \text{Ca}_{\text{opt}}) \cdot \left(1 - \frac{\text{stim}_{\text{Ca}}}{\text{stim}_{\text{Ca}}} \delta_0\right) - \pi_s) \cdot \epsilon_{\text{Ca}}, \tag{10}
\]

\[
\frac{d\pi_p}{dt} = (\text{stim}_{\text{P}}(P - P_{\text{opt}}) \cdot \left(1 - \frac{\text{stim}_{\text{P}}}{\text{stim}_{\text{P}}} \pi_p\right) - \pi_p) \cdot \epsilon_{\text{P}}. \tag{11}
\]

Again, $p_o$ and $n_o$ determine the intensity of the stimulus on the activity, whereas the time constants $\epsilon_{\text{Ca}}$ and $\epsilon_{\text{P}}$ determine the critical time with which the system responds to the stimulus. We use these sets of equations for the cellular degradation rate ($s = d$), PTH production rate ($s = p$), and cell proliferation rate ($s = pr$).

**Parathyroid hormone**

There is a well-known sigmoidal relationship between Ca$^{2+}$ and PTH release rate (Grant et al. 1990; Felsenfeld et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007). We use a previously published model for PTH allowing the storage of PTH in the gland (Brown et al. 2007).
Parathyroid gland cell populations

Our PTG model employs two cell populations, active secretory cells S and quiescent cells Q. PTG cells cycle through the two states (Fig. 5). Cells in the quiescent state can proliferate or undergo apoptosis and – when left untreated – enhanced cell proliferation will lead to PTG hyperplasia. We capture this behavior by a growth model with dynamic carrying capacity $K$ (Ribba et al. 2011; Benzekry et al. 2014). Associating the total number of cells in the quiescent state with the volume, we use the following model:

\[
\frac{dS}{dt} = -k_{SQ} S + k_{QS} Q, \quad (15)
\]

\[
\frac{dQ}{dt} = k_{SQ} S - k_{QS} Q - k_a Q + k_p Q \ln(K/(S + Q)), \quad (16)
\]

\[
\frac{dK}{dt} = k_k ((S + Q)/(S_0 + Q_0) - 1)^{2/3}, \quad (17)
\]

where $k_{SQ}$ and $k_{QS}$ are constant rates determining the cell cycle between the secretory active and quiescent state, $k_a$ is the constant apoptosis rate, and the constant $k_k$ is the rate with which the dynamic growth capacity $K$ adjusts to the size of the gland. The size of the healthy gland is estimated by the initial steady state $S_0 = S(0), Q_0 = Q(0)$.

**Intracellular degradation rate of PTH**

Under normal conditions (i.e., $C_d \geq 1$), CaSR keeps the cellular degradation of PTH $k_d$ at a basal rate of $A_d$. If not regulated by the CaSR, this rate will decrease to a minimum rate of $B_d = 0.5 \cdot A_d$ (Brown 2015):

\[
k_d = B_d + (A_d - B_d) \cdot C_d \quad \text{for} \quad C_d < 1, \quad (18)
\]

where $A_d$ and $B_d$ are constants.

**PTH production rate**

PTH is constantly produced by secretory active PTG cells with a basal rate of $A_p$. Again, if not downregulated by the CaSR, the production rate $k_p$ will increase within minutes to hours to a maximum level of $B_p = 2 \cdot A_p$ (Brown 2015):
where \(A_p\) and \(B_p\) are constants.

### Proliferation rate

The cell proliferation rate \(k_{pr}\) increases from the basal level \(A_{pr}\) to a maximum rate of \(B_{pr} = 2 \cdot A_{pr}\) if not down-regulated by the CaSR \(\text{Wang et al. 1997; Tokumoto et al. 2005)}:\)

\[
k_{pr} = B_{pr} + (A_{pr} - B_{pr}) \cdot C_{pr} \text{ for } C_{pr} < 1,
\]

where \(A_{pr}\) and \(B_{pr}\) are constants.

### Parameters and sensitivity analysis

The only parameters estimated for the simulations are the ones associated with the intensities of the feedback systems (Equations (1), (2), (6), and (9)).

All basic parameters for PTG, PTH release, and intracellular degradation are based on literature (Table 1). Basic parameters for the stimulus functions (Table 2) are chosen such that the derivative of the stimulus function is maximal around the critical values (Ca\(^{2+}\) arterial blood: 4.4–6.6 mg/dL and the mean derivative in the reference ionized calcium): 2.8 mg/dL, 1,25D: 90 ng/mL, P: 6.6 mg/dL) and the mean derivative in the reference range (Ca\(^{2+}\): 4.4–5.5 mg/dL, 1,25D: 20–60 ng/dL, P: 3.4–4.5 mg/dL) is smaller than 0.08 for Ca\(^{2+}\) and P and 0.0035 for 1,25D. The value for 1,25D is much smaller since it is not as tightly regulated as the other two parameters.

Time constants are chosen such that the effect of the stimulus is physiologically appropriate (Table 3). All alterations with the exception of cellular proliferation reach a steady state. Therefore, the only time constant relevant for long-term adaptations is the one associated with cellular proliferation. We assessed the impact of uncertainties in the time constant by multiplying or dividing the base time constants (Equations (10) and (11)) governing the response of the cellular proliferation rate to the stimulus (Equation (14)) one at a time by a factor of 10 while keeping all other parameters constant and simulating a mild hypocalcemia and hyperphosphatemia. We then analyzed the corresponding PTH predictions. The analysis revealed that the system is not sensitive to the alterations of the time constants. Even after 30 days, the difference in PTH is below 0.009% for changes in phosphate-related values and below 0.003% for changes in calcium-related values.

The sensitivities of PTH predictions related to uncertainties of intensities of the stimulation functions where assessed by multiplying or dividing the base values by a factor of 2 one at a time while keeping all other parameters constant. PTH was simulated for 7 days under the condition of normocalcemia, developing hyperphosphatemia, and declining 1,25D levels. The analysis revealed the highest sensitivity to changes of \(P_{Ca}\) and \(n_{Ca}\) associated with PTH production rate (Equations (9), (13)) and to changes of \(P_{Ca}\) and \(n_{Ca}\) of the CaSR (Equations (1)–(2))

---

### Table 1. Basic set of parameters for the parathyroid gland, PTH release, and intracellular degradation

| Compartment | Parameter | Value | Source |
|-------------|-----------|-------|--------|
| PTG         | \(k_{SQ}\) | \(2.10^{-3}/\text{min}\) | Raposo et al. (2002) |
| PTH release | \(A\)   | \(0.12 \text{ pmol/min}\) | Shrestha et al. (2010) |
|             | \(B\)   | \(0.001 \text{ pmol/min}\) | Shrestha et al. (2010) |
| Clearan    | \(k_c\) | \(0.632/\text{min}\) | Shrestha et al. (2010) |
| Degradation| \(A_{0}^{d}\) | \(0.012/\text{min}\) | Shrestha et al. (2010) |
| Production | \(A_{pr}\) | \(132\) | Shrestha et al. (2010) |
| Proliferation | \(A_{p}\) | \(0.003/\text{min}\) | Fukagawa et al. (1990) |
|            | \(k_k\) | \(5 \cdot 10^{-5}\) | |

\(k_{SQ}\) is chosen such that the fraction of active cells at steady state is 0.2.

### Table 2. Basic set of parameters for the stimulation functions.

| Compartment | Parameter | Value |
|-------------|-----------|-------|
| Optimal values | \(C\) | \(5 \text{ mg/dL}\) |
|              | \(P\) | \(4.5 \text{ mg/dL}\) |
|              | \(D\) | \(45 \text{ pg/mL}\) |
| Stimulus     | \(C_1\) | \(2 \text{ mg/dL}\) |
|              | \(K_c\) | \(2 \text{ dL/mg}\) |
|              | \(D_1\) | \(45 \text{ ng/ml}\) |
|              | \(K_D\) | \(0.2 \text{ mL/ng}\) |
|              | \(P_1\) | \(2.5 \text{ mg/dL}\) |
|              | \(K_p\) | \(2.5 \text{ dL/mg}\) |
determining the steady state of the CaSR expression. The sensitivity plot is presented in Figure 6. Steady state values are directly calculated from the equations. For our basic set of parameters, these values are $S_0 = 0.1934$, $Q_0 = 0.7738$, $K_0 = 1$, and $PTG_0 = 565$. The steady state concentration of PTH is 3.15 pmol/L. Since we start at the optimal condition, all steady state values of the stimulus functions (e.g., $v_{in}/C_1^{4}$) are zero and all steady state values of the functions accounting for the effect of the stimulus on the receptor (e.g., $v_0$) are 1.

**Results**

**Acute response**

The acute response of PTH to hypocalcemia depends on the rate of Ca$^{2+}$ reduction (Brent et al. 1988; Conlin et al. 1989; Grant et al. 1990; Schmitt et al. 1996; Estepa et al. 1999; Felsenfeld et al. 2007). In a study in dogs, a linear drop by 1.6 mg/dl Ca$^{2+}$ within 30 minutes produced a prominent PTH peak. A linear drop of the same amount within 120 minutes did not produce a prominent PTH peak.
peak but higher PTH concentrations after around 60 minutes (Estepa et al. 1999; Felsenfeld et al. 2007) Figure 7. The same characteristics regarding the fast decline of Ca\textsuperscript{2+} were found in rats (Schmitt et al. 1996). The absence of PTH overshoot in CKD patients was reported by Messa and coworkers (Messa et al. 1994).

We simulate acute Ca\textsuperscript{2+} change by starting from the system steady state and changing the ionized calcium concentration at different rates. Due to the storage of PTH in the secretory active cells, fast induction of hypocalcemia (5% reduction of Ca\textsuperscript{2+} within 30 minutes) leads to the clinically observed PTH overshoot followed by a sharp decline, while slow induction of hypocalcemia (5% reduction of Ca\textsuperscript{2+} within 120 minutes) leads to a small PTH overshoot before reaching levels similar to those of the fast reduction protocol (Fig. 8).

**Hysteresis**

Schwarz and coworkers (Schwarz et al. 1998) used induced hypocalcemia followed by a brief return to normocalcemia and a subsequent hypocalcemia to analyze PTH hysteresis effects. After a sharp increase of PTH during the first peak of 0.8 mg/dl from Ca\textsuperscript{2+} baseline levels and a slight drop due to the return to normal, the authors did not observe a second transient PTH peak (Fig. 9).

We simulate this protocol and find the same PTH dynamics – a prominent peak during the first hypocalcemia (due to the quick release of PTH stored in the PTG cells) and no peak during the second hypocalcemia (since recovery time in the normocalcemic condition is insufficient to load the PTH storage again) (Fig. 10).

**Secondary hyperparathyroidism**

Mild chronic hypocalcemia will trigger all mechanisms resulting in elevated PTH levels (Brown 2015) (Fig. 1). We simulate chronic hypocalcemia by lowering Ca\textsuperscript{2+} by 0.25 mg/dL and keeping it low for 200 days. Due to the slight decline in CaSR expression, the decrease in intracellular degradation, the increase in PTH production rate, and the slight increase in cellular proliferation, PTH levels will not reach a steady state but rather increase slightly but steadily (Fig. 11).

A steady increase of PTH can also be observed if Ca\textsuperscript{2+} is kept at an optimal value, but 1,25D is reduced (e.g., due to impaired synthesis), and phosphate levels are
elevated (e.g., due to impaired clearance). Although there
is no prominent PTH peak because Ca\textsuperscript{2+} is maintained at
the optimal level, the PTH concentration will continu-
ously increase and not reach a steady state due to the loss
of CaSR expression and sensitivity and the increased cel-
lar proliferation. In 1977, Rutherford and colleagues
(Rutherford et al. 1977) reported long-term effects of a
regular phosphate diet and a low phosphate diet on PTH
levels in 5/6 nephrectomized dogs. PTH levels of dogs on
regular phosphate intake rose steadily over the 2 years;
the endpoint being almost 10-fold above the normal
levels. An increase in the slope was significantly lower if
phosphate intake was lowered in line with the decreased
glomerular filtration rate (Fig. 12). We predict the same
effect with our model. We observe a slower incline if
phosphate is elevated only slightly over time (Fig. 13).

**Discussion**

Predictions generated with our model agree with observed
PTH response and PTG adaptation in a number of acute
and chronic alterations of Ca\textsuperscript{2+}, P, and 1,25D. The model
accurately accounts for adaptation mechanisms such as
decreased intracellular PTH degradation, PTH production
rate, and elevated PTG proliferation rate. More impor-
tantly, it fully captures the different timescales, these
mechanisms are acting on. The driving force of the PTG
model is the description of changes in the CaSR which is
the crucial regulator of the PTG. We validated our model
by comparing its predictions with published experimental
data under different conditions. The model predictions
agree with observations in all analyzed scenarios, that is, different rates of induced hypocalcemia (Brent et al. 1988), hysteresis (Conlin et al. 1989; Schwarz et al. 1998), hyperplasia in the case of induced chronic mild hypocalcemia (Brown 2015), and secondary hyperparathyroidism in the case of chronically elevated serum phosphate levels as well as chronically low 1,25DH levels (Fukagawa et al. 1990; Quarles et al. 1994; Slatopolsky et al. 1999; Toku-moto et al. 2005; Brown 2015). This feature makes the model particularly interesting in patients suffering from secondary hyperparathyroidism, such as those with CKD or on dialysis.

To our best knowledge, the proposed model is the first to include all of the known adaptive mechanisms which regulate the CaSR. The predictions are based on positive and negative feedback systems acting on the CaSR. The effect of therapeutic interventions acting on the CaSR, such as the calcimimetic drugs cinacalcet or etelcalcetide (Block et al. 2004; Valle et al. 2008; Padhi and Harris 2009), can be easily incorporated by using an operational model of allosterism on the CaSR (Leach et al. 2007, 2010, 2016; Roche et al. 2013). Therefore, the model provides a complementary tool to study treatment strategies like combinations of calcimimetics and vitamin D analogs (Teng et al. 2003).

A limitation of the model is the control of extracellular levels of ionized Ca$^{2+}$, 1,25D, and phosphate since in reality these concentrations are themselves affected by PTH release. We deliberately accept this limitation for the sake of clarity. The control of the parameters provides us the opportunity to study isolated effects of alterations in each individual parameter on the parathyroid gland biology. However, since these key regulators of PTG cells in hemodialysis patients are the only input parameters, the model can be easily combined with a bone model, for example (Peterson and Riggs 2010), allowing the analysis of a highly complex system involving a cascade of regulatory triggers and feedback loops.

Another regulator of phosphate and calcium homeosta-sis, as well as PTH release in healthy subjects, is fibroblast growth factor 23 (FGF23) (White et al. 2000; Shimada et al. 2001). FGF23 decreases renal phosphate reabsorption and thus increases renal phosphate excretion. Due to a negative feedback loop with 1,25D, FGF-23 regulates intestinal phosphate and calcium absorption (Shimada et al. 2004; Liu et al. 2006; Quarles 2012). Moreover, FGF23 inhibits PTH secretion and synthesis (Ben-Dov et al. 2007), whereas PTH stimulates FGF23 creating another negative feedback loop (Kawata et al. 2007). At early stages of CKD, FGF23 prevents hyperphosphatemia by promoting phosphaturia and decreasing 1,25D leading to a reduction in phosphate absorption and enhancement of renal phosphate excretion (Gutierrez et al. 2005; Jueppner et al. 2010). However, as renal function declines, the increased FGF23 can no longer increase phosphate excretion. The role of FGF23 in dialysis patients, with negable phosphate excretion, is not clear. While FGF23 is associated with poor clinical outcome (Isakova et al. 2011), it might not be an independent predictor (Isakova et al. 2015). Despite up to 100-fold elevated levels of FGF23 in hemodialysis patients, most of these patients develop severe secondary hyperparathyroidism (Komaba and Fukagawa 2012). In a recent study, Mace and coworkers (Mace et al. 2018) showed that FGF23 inhibits PTH synthesis and secretion in normocalcemia. However, during acute hypocalcemia, where increased
PTH levels are necessary to reverse hypocalcemia, no inhibitory effect of FGF23 on PTH secretion was observed. Hence, despite having a crucial role for phosphate homeostasis in healthy subjects, due to the absence of a functioning kidney and the failing downregulation of PTH, secretion of FGF23 is omitted in this model.

While we modeled the situation of hemodialysis patients with total loss of the kidney function as a system regulator, the model is more generally applicable to other patients groups, for example, patients suffering from primary hyperparathyroidism. The only parameter which is directly influenced by the kidney function is the clearance rate, \( k_d \). Since PTH is cleared by the liver and the kidney, the clearance rate is higher in healthy subjects (Table 1) or CKD patients with residual kidney function. For our long-term simulations, we assumed that the clearance rate is reduced by a factor 2. However, in the well-controlled system present in healthy subjects, the model is significantly simplified in that calcium homeostasis is quickly restored in the presence of disturbances. As a result, the long-term adaptation mechanisms are of no importance.

In this model, we capture the physiological regulation of the parathyroid gland. Further efforts will be undertaken to include pharmacological control of the PTG such as the effect of calcimimetics on PTH levels. The pharmacological control of PTG involves some adjustments such as the reversibility of hyperplasia due to the administration of calcimimetics (Drueke et al. 2007; Jean et al. 2007; Meola et al. 2009).

In conclusion, our model captures all the major regulators of PTG biology which are operative in patients with CKD and those on hemodialysis, thereby allowing us to study a multitude of sequelae, including some aspects of secondary hyperparathyroidism. Furthermore, the model can be extended with mathematical models describing bone remodeling and intestinal calcium and phosphate absorption, thus allowing a detailed study of CKD-MBD.

**Conflict of Interest**

Peter Kotanko holds stock in Fresenius Medical Care.

**References**

Ben-Dov, I. Z., H. Galitzer, V. Lavi-Moshayoff, R. Goetz, M. Kuro-o, M. Mohammadi, et al. 2007. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117:4003–4008.

Benzekry, S., C. Lamont, A. Beheshti, A. Tracz, J. M. L. Ebos, L. Hlatky, et al. 2014. Classical mathematical models for description and prediction of experimental tumor growth. PLoS Comput. Biol. 10:e1003800.

Block, G., K. Martin, A. de Francisco, S. Turner, M. Avram, M. Suranyi, et al. 2004. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350:1516–1525.

Borrego, M., A. Felsenfeld, A. Martin-Malo, Y. Almaden, M. Concepcion, P. Aljama, et al. 1997. Evidence for adaptation of the entire PTH-calcium curve to sustained changes in the serum calcium in haemodialysis patients. Nephrol. Dial. Transplant. 12:505–513.

Brea, J., M. Castro, J. Giraldo, J. F. Lopez-Gimenez, J. Fernando Padin, F. Quintian, et al. 2009. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol. Pharmacol. 75:1380–1391.

Brent, G., M. Leboff, E. Seely, P. Conlin, and E. Brown. 1988. Relationship between the concentration and rate of change of calcium and serum intact parathyroid-hormone levels in normal humans. J. Clin. Endocrinol. Metab. 67:944–950.

Brown, E. 1983. 4-parameter model of the sigmoidal relationship between parathyroid-hormone release and extracellular calcium-concentration in normal and abnormal parathyroid tissue. J. Clin. Endocrinol. Metab. 56:572–581.

Brown, E. M. 2007. Clinical lessons from the calcium-sensing receptor. Nat. Clin. Pract. Endocrinol. Metab. 3:122–133.

Brown, E. 2015. Control of parathyroid hormone secretion by its key physiological regulators. Pp. 101–108 in J. Bilezikian, ed. The Parathyroids: basic and Clinical Concepts. Elsevier, USA.

Brown, E., R. Leonbruno, J. Thatcher, and M. Burrowes. 1985. The acute secretory response to alterations in extracellular calcium-concentration and dopamine in perfused bovine parathyroid cells. Endocrinology 116:1123–1132.

Brown, A., C. Ritter, J. Finch, and E. Slatopolsky. 1999. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: role of dietary phosphate. Kidney Int. 55:1284–1292.

Canalejo, A., Y. Almaden, V. Torregrosa, J. Gomez-Villamandos, B. Ramos, J. Campistol, et al. 2000. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J. Am. Soc. Nephrol. 11:1865–1872.

Chakravarti, B., N. Chattopadhyay, and E. M. Brown. 2012. Signaling through the extracellular calcium-sensing receptor (CaSR). Adv. Exp. Med. Biol. 740:103–142.

Chen, R., and W. Goodman. 2004. Role of the calcium-sensing receptor in parathyroid gland physiology. Am. J. Physiol. Renal. Physiol. 286:F1005–F1011.

Conigrave, A. D., and D. T. Ward. 2013. Calcium-sensing receptor (CaSR): pharmacological properties and signaling pathways. Best Pract. Res. Clin. Endocrinol. Metab. 27:315–331.

Conlin, P., V. Fajtova, R. Mortensen, M. Leboff, and E. Brown. 1989. Hysteresis in the relationship between serum
ionized calcium and intact parathyroid-hormone during recovery from induced hypercalcemia and hypocalcemia in normal humans. J. Clin. Endocrinol. Metab. 69:593–599.

Denda, M., J. Finch, and E. Slatopolsky. 1996. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am. J. Kidney Dis. 28:596–602.

Drueke, T., D. Martin, and M. Rodriguez. 2007. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial Transplant 22:1828–1839.

Estepa, J., E. Aguilera-Tejero, Y. Almaden, M. Rodriguez, and A. Felsenfeld. 1999. Effect of rate of calcium reduction and a hypocalcemic clamp on parathyroid hormone secretion: a study in dogs. Kidney Int. 55:1724–1733.

Felsenfeld, A. J., M. Rodriguez, and E. Aguilera-Tejero. 2007. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 2:1283–1305.

Fukagawa, M., R. Okazaki, K. Takano, S. Kaname, E. Ogata, M. Kitaoaka, et al. 1990. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N. Engl. J. Med. 323:421–422.

Fukagawa, M., S. Nakanishi, and J. J. Kazama. 2006. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 70:S3–S7.

Gogusev, J., P. Duchambron, B. Hory, M. Giovannini, Y. Goureau, E. Sarfati, et al. 1997. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 51:328–336.

Goodman, W. G., and L. D. Quarles. 2008. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int. 74:276–288.

Goodman, W., J. Veldhuis, T. Belin, A. Van Herle, H. Juppner, and I. Salusky. 1998. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 83:2765–2772.

Graciolli, D., O. Bonny, and A. Edwards. 2017. Coupling between phosphate and calcium homeostasis: a mathematical model. Am. J. Physiol. Renal. Physiol. 313: F1181–F1199.

Grant, F., P. Conlin, and E. Brown. 1990. Rate and concentration-dependence of parathyroid-hormone dynamics during stepwise changes in serum ionized calcium in normal humans. J. Clin. Endocrinol. Metab. 71:370–378.

Gutierrez, O., T. Isakova, E. Rhee, A. Shah, J. Holmes, G. Collerone, et al. 2005. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 16:2205–2215.

Habener, J. 1981. Regulation of parathyroid-hormone secretion and biosynthesis. Annu. Rev. Physiol. 43:211–223.

Isakova, T., H. Xie, W. Yang, D. Xie, A. H. Anderson, J. Scialla, et al.; CRIC Study Grp. 2011. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439.

Isakova, T., T. E. Craven, J. Lee, J. J. Scialla, H. Xie, P. Wahl, et al. 2015. Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clin. J. Am. Soc. Nephrol. 10:29–38.

Jean, G., C. Chazot, and B. Charra. 2007. Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism. Nephrol. Dial Transplant. 22:2102–2103.

Jueppner, H., M. Wolf, and I. B. Salusky. 2010. FGF-23: more than a regulator of renal phosphate handling? J. Bone Miner. Res. 25:2091–2097.

Kawata, T., Y. Imanishi, K. Kobayashi, T. Miki, A. Arnold, M. Inaba, et al. 2007. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 18:2683–2688.

Komaba, H., and M. Fukagawa. 2012. The role of FGF23 in CKD-with or without Klotho. Nat. Rev. Nephrol. 8:484–490.

Kroll, M. 2000. Parathyroid hormone temporal effects on bone formation and resorption. Bull. Math. Biol. 62:163–188.

Leach, K., P. M. Sexton, and A. Christopoulos. 2007. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28:382–389.

Leach, K., R. E. Loiacono, C. C. Felder, D. L. McKinzie, A. Mogg, D. B. Shaw, et al. 2010. Molecular mechanisms of action and in vivo validation of an M-4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 35:855–869.

Leach, K., K. J. Gregory, I. Kufareva, E. Khajehali, A. E. Cook, R. Abagyan, et al. 2016. Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Res. 26:574–592.

Lemaire, V., F. Tobin, L. Greller, C. Cho, and L. Suva. 2004. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J. Theor. Biol. 229:293–309.

Levin, A., G. L. Bakris, M. Molitch, M. Smulders, I. Tian, L. A. Williams, et al. 2007. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71:31–38.

Liu, S., W. Tang, J. Zhou, J. Stubbs, Q. Luo, M. Pi, et al. 2006. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 17:1305–1315.

Mace, M. L., E. Gravesen, A. Nordholm, K. Olggaard, and E. Levin. 2018. Fibroblast growth factor (FGF) 23 regulates the plasma levels of parathyroid hormone in vivo through the FGF receptor in normocalcemia, but not in hypocalcemia. Calcif. Tissue Int. 102:85–92.
Meola, M., I. Petrucci, and G. Barsotti. 2009. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol. Dial Transplant. 24:982–989.

Messa, P., C. Vallone, G. Mioni, O. GeattiI, D. Turrin, N. Passoni, et al. 1994. Direct in-vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int. 46:1713–1720.

Moallem, E., R. Kilav, J. Silver, and T. Naveh-Many. 1998. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J. Biol. Chem. 273:5253–5259.

Moe, S., T. Druke, J. Cunningham, W. Goodman, K. Martin, K. Olgarda, et al. 2006. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69:1945–1953.

Momsen, G., and P. Schwarz. 1997. A mathematical/physiological model of parathyroid hormone secretion in response to blood-ionized calcium lowering in vivo. Scand. J. Clin. Lab. Invest. 57:381–394.

Navehmany, T., R. Rahamimov, N. Livni, and J. Silver. 1995. Parathyroid cell-proliferation in normal and chronic-renal-failure rats - the effects of calcium, phosphate, and vitamin-D. J. Clin. Invest. 96:1786–1793.

Nemeth, E. 2002. Pharmacological regulation of parathyroid hormone secretion. Curr. Pharm. Des. 8:2077–2087.

Padhi, D., and R. Harris. 2009. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin. Pharmacokinet. 48:303–311.

Palmer, S. C., A. Hayen, P. Macaskill, F. Pellegrini, J. C. Craig, G. J. Elder, et al. 2011. Serum levels of phosphorus parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis. JAMA 305:1119–1127.

Peterson, M. C., and M. M. Riggs. 2010. A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone 46:49–63.

Pocotte, S., G. Ehrenstein, and L. Fitzpatrick. 1991. Regulation of parathyroid-hormone secretion. Endocr. Rev. 12:291–301.

Quarles, L. D. 2012. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8:276–286.

Quarles, L., D. Yohay, B. Carroll, C. Spritzer, S. Minda, D. Bartholomay, et al. 1994. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in Esrd. Kidney Int. 45:1710–1721.

Raposo, J., L. Sobrinho, and H. Ferreira. 2002. A minimal mathematical model of calcium homeostasis. J. Clin. Endocrinol. Metab. 87:4330–4340.

Ribba, B., E. Watkin, M. Tod, P. Girard, E. Grenier, B. You, et al. 2011. A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers. Eur. J. Cancer 47:479–490.

Riggs, M. M., M. C. Peterson, and M. R. Gastonguay. 2012. Multiscale physiology-based modeling of mineral bone disorder in patients with impaired kidney function. J. Clin. Pharmacol. 52:45S–53S.

Roche, D., D. Gil, and J. Girald. 2013. Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models. Br. J. Pharmacol. 169:1189–1202.

Rutherford, W., P. Bordier, P. Marie, K. Hruska, H. Harter, A. Greenwalt, et al. 1977. Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in dog. J. Clin. Invest. 60:332–341.

Schmitt, C., and F. Schaefer. 1999. Calcium sensitivity of the parathyroid in renal failure: another look with new methodology. Nephrol. Dial Transplant. 14:2815–2818.

Schmitt, C., F. Schaefer, A. Bruch, J. Veldhuis, H. SchmidtGayk, G. Stein, et al. 1996. Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J. Clin. Endocrinol. Metab. 81:4236–4243.

Schwarz, P., H. Sorensen, P. McNair, and I. Transbol. 1993. Cica-clamp technique - a method for quantifying parathyroid-hormone secretion - a sequential citrate and calcium clamp study. Eur. J. Clin. Invest. 23:546–553.

Schwarz, P., J. Madsen, A. Rasmussen, I. Transbol, and E. Brown. 1998. Evidence for a role of intracellular stored parathyroid hormone in producing hysteresis of the PTH-calcium relationship in normal humans. Clin. Endocrinol. (Oxf) 48:725–732.

Shimada, T., S. Mizutani, T. Muto, T. Yoneya, R. Hino, S. Takeda, et al. 2001. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 98:6500–6505.

Shimada, T., H. Hasegawa, Y. Yamazaki, T. Muto, R. Hino, Y. Takeuchi, et al. 2004. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19:429–435.

Shrestha, R. P., C. V. Hollot, S. R. Chipkin, C. P. Schmitt, and Y. Chait. 2010. A mathematical model of parathyroid hormone response to acute changes in plasma ionized calcium concentration in humans. Math. Biosci. 226:46–57.

Silver, J., and T. Naveh-Many. 2009. Phosphate and the parathyroid. Kidney Int. 75:898–905.

Slatopolsky, E., A. Dusso, and A. Brown. 1999. The role of phosphorus in the of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. Am. J. Med. Sci. 317:370–376.

Takahashi, F., M. Denda, J. Finch, A. Brown, and E. Slatopolsky. 2002. Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int. 61:1332–1338.
Teng, M., M. Wolf, E. Lowrie, N. Ofsthun, J. Lazarus, and R. Thadhani. 2003. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349:446–456.

Tokumoto, M., M. Taniguchi, D. Matsuo, K. Tsuruya, H. Hirakata, M. Iida. 2005. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors. Ther. Apher. Dial. 9:S27–S34.

Valle, C., M. Rodriguez, R. Santamaria, Y. Almaden, M. E. Rodriguez, S. Canadillas, et al. 2008. Cinacalcet reduces the set point of the PTH-calcium curve. J. Am. Soc. Nephrol. 19:2430–2436.

Vervloet, M. C., S. Sezer, Z. A. Massy, L. Johansson, M. Cozzolino, D. Fouque; ERA-EDTA Working Grp Chronic Kidney and European Renal Nutr Working Grp. 2017. The role of phosphate in kidney disease. Nat. Rev. Nephrol. 13:27–38.

Wang, M. D., H. Yin, R. Landick, J. Gelles, and S. M. Block. 1997. Stretching DNA with optical tweezers. Biophys. J. 72:1335–1346.

White, K., W. Evans, J. O’Riordan, M. Speer, M. Econs, B. Lorenz-Depiereux, et al.; ADHR Consortium. 2000. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 26:345–348.